any change in make/mark up and the notified price of the bulk drug;

(b) whether such increase has been allowed and based on addition of incidental costs which were not allowed earlier as the market price of the drugs involved was lower than the notified price;

(c) if so, what necessitated the reversal of the decision; and

(d) what is the locus standi of the Drug Prices Review Committee and to whom it is responsible?

THE MINISTER OF INDUSTRY (SHRI J. VENGALRAO): (a) to (c) Prices of a large number of formulations have been fixed/revised as per provisions of DPCO, 1987. Prices of Scheduled formulations depend on several factors in addition to the rate of MAPE and prices of bulk drug concerned, including incidental charges.

(d) The Drug Prices Review Committee is an interministerial Committee which sends its recommndations to the Deptt. of Chemicals and Petro-Chemicals in the Ministry of Industry.

Submission of details of Imports of Drug Intermediates

1561. DR. (SHRIMATI) NAJMA HEPTULLA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that as per provision 6.7 of measures 1986, all existing drug companies which import drug intermediates and other raw materials from their principals or their associated companies are required to submit the details of such transactions within a period of one month of such imports;

(b) if so, what are the names of the drug companies alongwith names of intermediates and other raw materials imported from their principals and associated companies during 1987;

(c) whether it is a fact that in a number of cases, there is over invoicing and transfer of pricing; and

(d) if so, what system has been evolved by his Ministry to check, monitor and scrutinise such cases?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir.

(b) to (c) No company has furnished any such transaction so far.

(d) Department of Chemicals and Petrochemicals scrutinise the details available in this regard.

Composition of monitoring cell for drug prices

1562. DR. (SHRIMATI) NAJMA HEPTULLA: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1358 given in the Rajya Sabha on the 9th May, 1988 and state:

(a) how many persons have been appointed in the monitoring cell to monitor the prices of drugs and what functions have been assigned to them;

(a) what are the names of the medicines in the decontrolled category the prices of which have been communicated to the cell and what were the prices of such medicines under DPCO, 1978;

(c) what were the prices of price-decontrolled antidiabeties cough syrups, ATS and vitamin preparation products by leading manufacturers under DPCO, 1979 and at present; and

(d) what are the areas covered by the monitoring cell and whether it is a fact that details of sales turnover are given by the manufacturers in their price revision applications?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Three officials have been appointed in the

monitoring cell to monitor the prices of non-scheduled bulk drugs/formulations.

(b) and (c) The required details are quite voluminous and are not readily available. The time and effort required for collection of these will not be commensurate with the results likely to be achieved.

(d) The cell monitors price changes of non-scheduled bulk drugs/formulations. Sales turnover is not monitored.

Marketing of dextropropoxyphene by M/s. Wockhardt

1563. DR. RATNAKAR PANDEY: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that dextropropoxyphene based formulations produced and marketed by Wockhardt are being marketed without any price approval;

(b) since when the process is going on and what is the present position; and

(c) what steps have been taken to calculate the amount overcharged and by when the company would be prosecuted and the excess amount recovered from it?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (c) To the extent information is available, M/s. Wockhardt have not applied for any price approval for formulations based on Dextropropoxyphene produced and marketed by them if any. The company has not submitted their price list in Form-5 under DPCO, 1987. The BICP has been requested to recommend the prices for such formulations sub-moto.

Settlement of formulation prices

1564. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) what are the names of non-scheduled bulk drugs and formulations for which the manufacturers have communicated their prices to his Ministry;

(b) what were their prices under DPCO 1979;

(c) what are the prices communicated by the manufacturers;

(d) whether it is a fact that his Ministry settled the prices for each of these bulk drug, and formulations;

(e) if so, what price was settled for each; and

(f) what is the procedure for settlement of price and what factors are being taken into consideration for such settlement?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) There are 27 bulk drugs and formulation in Schedule-I and 139 in Schedule-II. All other are price de-controlled. The required details in the question are quite voluminous and are not readily available. The time and effort required for collection of them will not be commensurate with the result likely to be achieved.

(f) As per the provisions of DPCO 1987, the manufacturers of non-scheduled bulk drugs/formulations are free to revise the prices. However, Government is keeping a watch and has intervened whrever found necessary.

Exhorbitant prices of certain drugs.

1565. PROF. C. LAKSHMANNA:
SHRI V. NARAYANASAMY:
SHRI RAM CHANDRA VIKAL:

Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that exhorbitant prices are being charged for Durabolin, Decadurabolin, Gestanon, Orabolin, Testoviron, Proluton-Dept and Dulcolax as the prices of these products have never been fixed in spite of monopolistic production;